Skip to main content
SpringerLink
Log in

Developing Biomarkers for MS

  • Chapter
  • First Online:
Emerging and Evolving Topics in Multiple Sclerosis Pathogenesis and Treatments

Part of the book series: Current Topics in Behavioral Neurosciences ((CTBN,volume 26))

Abstract

Existing clinical outcomes of disease activity, including relapse rates, are inherently insensitive to the underlying pathological process in MS. Moreover, it is extremely difficult to measure clinical disability in patients, which is often a retrospective assessment, and definitely not within the time frame of a clinical trial. Biomarkers , conversely are more specific for a pathologic process and if used correctly can prove invaluable in the diagnosis, stratification and monitoring of disease activity, including any subclinical activity which is not visible to the naked eye. In this chapter, we discuss the development of neurofilaments as surrogate outcomes of disability in MS. The validation and qualification are vital steps in biomarker development and to gaining acceptance in scientific community, and the pitfalls leading up to this are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Amor S, van der Star BJ, Bosca I, Raffel J, Gnanapavan S, Watchorn J, Kuhle J, Giovannoni G, Baker D, Malaspina A, Puentes F (2014) Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis. Multiple Sclerosis 20(10):1355–1362

    Article  PubMed  Google Scholar 

  • Avolio C, Ruggieri M, Giuliani F, Liuzzi GM, Leante R, Riccio P, Livrea P, Trojano M (2003) Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 136:46–53

    Article  CAS  PubMed  Google Scholar 

  • Axelsson M, Malmestrom C, Gunnarsson M, Zetterberg H, Sundstrom P, Lycke J, Svenningsson A (2014) Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Multiple Sclerosis 20:43–50

    Article  CAS  PubMed  Google Scholar 

  • Axelsson M, Malmestrom C, Nilsson S, Haghighi S, Rosengren L, Lycke J (2011) Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. J Neurol 258:882–888

    Article  CAS  PubMed  Google Scholar 

  • Balnyte R, Rastenyte D, Uloziene I, Mickeviciene D, Skordeniene E, Vitkauskiene A (2011) The significance of HLA DRB1*1501 and oligoclonal bands in multiple sclerosis: clinical features and disability. Medicina 47:368–373

    PubMed  Google Scholar 

  • Brettschneider J, Petzold A, Junker A, Tumani H (2006) Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Multiple Sclerosis 12:143–148

    Article  CAS  PubMed  Google Scholar 

  • Burman J, Zetterberg H, Fransson M, Loskog AS, Raininko R, Fagius J (2014) Assessing tissue damage in multiple sclerosis: a biomarker approach. Acta Neurol Scand 130(2):81–89

    Article  CAS  PubMed  Google Scholar 

  • Canto E, Reverter F, Morcillo-Suarez C, Matesanz F, Fernandez O, Izquierdo G, Vandenbroeck K, Rodriguez-Antiguedad A, Urcelay E, Arroyo R, Otaegui D, Olascoaga J, Saiz A, Navarro A, Sanchez A, Dominguez C, Caminero A, Horga A, Tintore M, Montalban X, Comabella M (2012) Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis. Multiple Sclerosis 18:983–990

    Article  CAS  PubMed  Google Scholar 

  • Colucci M, Roccatagliata L, Capello E, Narciso E, Latronico N, Tabaton M, Mancardi GL (2004) The 14-3-3 protein in multiple sclerosis: a marker of disease severity. Multiple Sclerosis 10:477–481

    Article  CAS  PubMed  Google Scholar 

  • Comabella M, Pericot I, Goertsches R, Nos C, Castillo M, Blas Navarro J, Rio J, Montalban X (2005). Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 158:231–239

    Article  CAS  PubMed  Google Scholar 

  • Cummings J, Raynaud F, Jones L, Sugar R, Dive C (2010) Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs. Br J Cancer 103:1313–1317

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Davenport RD, Keren DF (1988) Oligoclonal bands in cerebrospinal fluids: significance of corresponding bands in serum for diagnosis of multiple sclerosis. Clin Chem 34:764–765

    CAS  PubMed  Google Scholar 

  • Eikelenboom MJ, Petzold A, Lazeron RH, Silber E, Sharief M, Thompson EJ, Barkhof F, Giovannoni G, Polman CH, Uitdehaag BM (2003) Multiple sclerosis: neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 60:219–223

    Article  CAS  PubMed  Google Scholar 

  • Elder GA, Friedrich VL Jr, Kang C, Bosco P, Gourov A, Tu PH, Zhang B, Lee VM, Lazzarini RA (1998) Requirement of heavy neurofilament subunit in the development of axons with large calibers. J Cell Biol 143:195–205

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Fuchs E (1996) The cytoskeleton and disease: genetic disorders of intermediate filaments. Annu Rev Genet 30:197–231

    Article  CAS  PubMed  Google Scholar 

  • Giovannoni G, Nath A (2011) After the storm: neurofilament levels as a surrogate endpoint for neuroaxonal damage. Neurology 76:1200–1201

    Article  PubMed  Google Scholar 

  • Gisslen M, Hagberg L, Brew BJ, Cinque P, Price RW, Rosengren L (2007) Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis 195:1774–1778

    Article  CAS  PubMed  Google Scholar 

  • Gnanapavan S, Grant D, Morant S, Furby J, Hayton T, Teunissen CE, Leoni V, Marta M, Brenner R, Palace J, Miller DH, Kapoor R, Giovannoni G (2013) Biomarker report from the phase II lamotrigine trial in secondary progressive MS—neurofilament as a surrogate of disease progression. PLoS One 8:e70019

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Gnanapavan S, Grant D, Pryce G, Jackson S, Baker D, Giovannoni G (2012) Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitis. Autoimmunity 45:298–303

    Article  CAS  PubMed  Google Scholar 

  • Group BDW (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacololgy Ther 69:89–95

    Article  Google Scholar 

  • Gunnarsson M, Malmestrom C, Axelsson M, Sundstrom P, Dahle C, Vrethem M, Olsson T, Piehl F, Norgren N, Rosengren L, Svenningsson A, Lycke J (2011) Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 69:83–89

    Article  CAS  PubMed  Google Scholar 

  • Iaffaldano P, Ruggieri M, Viterbo RG, Mastrapasqua M, Trojano M (2014) The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis. Brain Behav Immun 35:96–101

    Article  Google Scholar 

  • Ingram G, Hakobyan S, Hirst CL, Harris CL, Pickersgill TP, Cossburn MD, Loveless S, Robertson NP, Morgan BP (2010). Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 133:1602–1611

    Article  PubMed  Google Scholar 

  • Irani DN, Kerr DA (2000) 14-3-3 Protein in the cerebrospinal fluid of patients with acute transverse myelitis. Lancet 355:901

    Article  CAS  PubMed  Google Scholar 

  • Jasperse B, Jakobs C, Eikelenboom MJ, Dijkstra CD, Uitdehaag BM, Barkhof F, Polman CH, Teunissen CE (2007) N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry. J Neurol 254:631–637

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Jaworski J, Psujek M, Janczarek M, Szczerbo-Trojanowska M, Bartosik-Psujek H (2012) Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy. Upsala J Med Sci 117:284–292

    Article  PubMed Central  PubMed  Google Scholar 

  • Jia Y, Wu T, Jelinek CA, Bielekova B, Chang L, Newsome S, Gnanapavan S, Giovannoni G, Chen D, Calabresi PA, Nath A, Cotter RJ (2012) Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS). Clin Proteomics 9(1):9

    Article  PubMed Central  PubMed  Google Scholar 

  • Jung K, Lein M, Laube C, Lichtinghagen R (2001) Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta 314(1–2):241–244

    Article  CAS  PubMed  Google Scholar 

  • Kapaki E Paraskevas GP, Michalopoulou M, Kilidireas K (2000) Increased cerebrospinal fluid tau protein in multiple sclerosis. Eur Neurol 43:228–232

    Article  CAS  PubMed  Google Scholar 

  • Karlsson JE, Rosengren LE, Haglid KG (1989) Polyclonal antisera to the individual neurofilament triplet proteins: a characterization using ELISA and immunoblotting. J Neurochem 53:759–765

    Article  CAS  PubMed  Google Scholar 

  • Khademi M, Dring AM, Gilthorpe JD, Wuolikainen A, Al Nimer F, Harris RA, Andersson M, Brundin L, Piehl F, Olsson T, Svenningsson A (2013) Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers. PLoS One 8:e63172

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Khalil M, Enzinger C, Langkammer C, Ropele S, Mader A, Trentini A, Vane ML, Wallner-Blazek M, Bachmaier G, Archelos JJ, Koel-Simmelink MJ, Blankenstein MA, Fuchs S, Fazekas F, Teunissen CE (2013) CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Multiple Sclerosis 19:436–442

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Kivisakk P, Healy BC, Francois K, Gandhi R, Gholipour T, Egorova S, Sevdalinova V, Quintana F, Chitnis T, Weiner HL, Khoury SJ (2014) Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Multiple Sclerosis 20:438–444

    Article  PubMed  Google Scholar 

  • Koel-Simmelink MJ, Vennegoor A, Killestein J, Blankenstein MA, Norgren N, Korth C, Teunissen CE (2014) The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA. J Immunol Methods 402:43–49

    Article  CAS  PubMed  Google Scholar 

  • Kuhle J, Leppert D, Petzold A, Regeniter A, Schindler C, Mehling M, Anthony DC, Kappos L, Lindberg RL (2011) Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology 76:1206–1213

    Article  CAS  PubMed  Google Scholar 

  • Kuhle J, Malmestrom C, Axelsson M, Plattner K, Yaldizli O, Derfuss T, Giovannoni G, Kappos L, Lycke J (2013a) Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol Scand 128:e33–e36

    Google Scholar 

  • Kuhle J, Plattner K, Bestwick JP, Lindberg RL, Ramagopalan SV, Norgren N, Nissim A, Malaspina A, Leppert D, Giovannoni G, Kappos L (2013b) A comparative study of CSF neurofilament light and heavy chain protein in MS. Multiple Sclerosis 19:1597–1603

    Article  PubMed  Google Scholar 

  • Kuhle J, Stites T, Chen Y, Dahlke F, Francis G, Sfikas N, Radue E-W, Giovannoni G, Kappos L (2013c) CSF neurofilament light chain are markedly reduced by fingolimod in relapsing remitting multiple sclerosis. Multiple Sclerosis 19:559–573

    Article  Google Scholar 

  • Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, Keller S, Weinryb I, Green M, Duan L, Rogers JA, Millham R, O’Brien PJ, Sailstad J, Khan M, Ray C, Wagner JA (2006) Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 23:312–328

    Article  CAS  PubMed  Google Scholar 

  • Lee JW, Hall M (2009) Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. J Chromatogr B 877(13):1259–1271

    Article  CAS  Google Scholar 

  • Lim ET, Grant D, Pashenkov M, Keir G, Thompson EJ, Soderstrom M, Giovannoni G (2004) Cerebrospinal fluid levels of brain specific proteins in optic neuritis. Multiple Sclerosis 10:261–265

    Article  CAS  PubMed  Google Scholar 

  • Lim ET, Sellebjerg F, Jensen CV, Altmann DR, Grant D, Keir G, Thompson EJ, Giovannoni G (2005) Acute axonal damage predicts clinical outcome in patients with multiple sclerosis. Multiple Sclerosis 11:532–536

    Article  CAS  PubMed  Google Scholar 

  • Liu Q, Xie F, Siedlak SL, Nunomura A, Honda K, Moreira PI, Zhua X, Smith MA, Perry G (2004) Neurofilament proteins in neurodegenerative diseases. Cell Mol Life Sci 61:3057–3075

    Article  CAS  PubMed  Google Scholar 

  • Lycke JN, Karlsson JE, Andersen O, Rosengren LE (1998) Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 64:402–404

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Madeddu R, Farace C, Tolu P, Solinas G, Asara Y, Sotgiu MA, Delogu LG, Prados JC, Sotgiu S, Montella A (2013) Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis. Neurol Sci 34:181–186

    Article  PubMed  Google Scholar 

  • Magraner MJ, Bosca I, Simo-Castello M, Garcia-Marti G, Alberich-Bayarri A, Coret F, Alvarez-Cermeno JC, Marti-Bonmati L, Villar LM, Casanova B (2012) Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes. Neuroradiology 54:5–12

    Article  PubMed  Google Scholar 

  • Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J (2003) Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 61:1720–1725

    Article  CAS  PubMed  Google Scholar 

  • Martinez-Yelamos A, Rovira A, Sanchez-Valle R, Martinez-Yelamos S, Tintore M, Blanco Y, Graus F, Montalban X, Arbizu T, Saiz A (2004a) CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS. J Neurol 251:1278–1279

    Article  CAS  PubMed  Google Scholar 

  • Martinez-Yelamos A, Saiz A, Bas J, Hernandez JJ, Graus F, Arbizu T (2004b) Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis. Neurosci Lett 363:14–17

    Article  CAS  PubMed  Google Scholar 

  • McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127

    Article  CAS  PubMed  Google Scholar 

  • McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) (REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235

    Article  PubMed  Google Scholar 

  • Modvig S, Degn M, Horwitz H, Cramer SP, Larsson HB, Wanscher B, Sellebjerg F, Frederiksen JL (2013) Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis. PLoS One 8:e77163

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Morris JR, Lasek RJ (1982) Stable polymers of the axonal cytoskeleton: the axoplasmic ghost. J Cell Biol 92:192–198

    Article  CAS  PubMed  Google Scholar 

  • Morris JR, Lasek RJ (1984) Monomer-polymer equilibria in the axon: direct measurement of tubulin and actin as polymer and monomer in axoplasm. J Cell Biol 98:2064–2076

    Article  CAS  PubMed  Google Scholar 

  • Norgren N, Sundstrom P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M (2004) Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 63:1586–1590

    Article  CAS  PubMed  Google Scholar 

  • Nylen K, Csajbok LZ, Ost M, Rashid A, Karlsson JE, Blennow K, Nellgard B, Rosengren L (2006) CSF—neurofilament correlates with outcome after aneurysmal subarachnoid hemorrhage. Neurosci Lett 404:132–136

    Article  CAS  PubMed  Google Scholar 

  • Peltola J, Ukkonen M, Moilanen E, Elovaara I (2001) Increased nitric oxide products in CSF in primary progressive MS may reflect brain atrophy. Neurology 57:895–896

    Article  CAS  PubMed  Google Scholar 

  • Petzold A, Altintas A, Andreoni L, Bartos A, Berthele A, Blankenstein MA, Buee L, Castellazzi M, Cepok S, Comabella M, Constantinescu CS, Deisenhammer F, Deniz G, Erten G, Espino M, Fainardi E, Franciotta D, Freedman MS, Giedraitis V, Gilhus NE, Giovannoni G, Glabinski A, Grieb P, Hartung HP, Hemmer B, Herukka SK, Hintzen R, Ingelsson M, Jackson S, Jacobsen S, Jafari N, Jalosinski M, Jarius S, Kapaki E, Kieseier BC, Koel-Simmelink MJ, Kornhuber J, Kuhle J, Kurzepa J, Lalive PH, Lannfelt L, Lehmensiek V, Lewczuk P, Livrea P, Marnetto F, Martino D, Menge T, Norgren N, Papuc E, Paraskevas GP, Pirttila T, Rajda C, Rejdak K, Ricny J, Ripova D, Rosengren L, Ruggieri M, Schraen S, Shaw G, Sindic C, Siva A, Stigbrand T, Stonebridge I, Topcular B, Trojano M, Tumani H, Twaalfhoven HA, Vecsei L, Van Pesch V, Vanderstichele H, Vedeler C, Verbeek MM, Villar LM, Weissert R, Wildemann B, Yang C, Yao K, Teunissen CE (2010a) Neurofilament ELISA validation. J Immunol Methods 352:23–31

    Article  CAS  PubMed  Google Scholar 

  • Petzold A, Eikelenboom MJ, Gveric D, Keir G, Chapman M, Lazeron RH, Cuzner ML, Polman CH, Uitdehaag BM, Thompson EJ, Giovannoni G (2002) Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 125:1462–1473

    Article  CAS  PubMed  Google Scholar 

  • Petzold A, Keir G, Green AJ, Giovannoni G, Thompson EJ (2003) A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 278:179–190

    Google Scholar 

  • Petzold A, Mondria T, Kuhle J, Rocca MA, Cornelissen J, te Boekhorst P, Lowenberg B, Giovannoni G, Filippi M, Kappos L, Hintzen R (2010b) Evidence for acute neurotoxicity after chemotherapy. Ann Neurol 68:806–815

    Article  PubMed  Google Scholar 

  • Petzold A, Plant GT (2012) The diagnostic and prognostic value of neurofilament heavy chain levels in immune-mediated optic neuropathies. Multiple Sclerosis Int 2012:217802

    Article  Google Scholar 

  • Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302

    Article  PubMed Central  PubMed  Google Scholar 

  • Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Ann Neurol 58:840–846

    Article  PubMed  Google Scholar 

  • Prentice RL (1989) Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8:431–440

    Article  CAS  PubMed  Google Scholar 

  • Rejdak K, Eikelenboom MJ, Petzold A, Thompson EJ, Stelmasiak Z, Lazeron RH, Barkhof F, Polman CH, Uitdehaag BM, Giovannoni G (2004) CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology 63:1439–1445

    Article  CAS  PubMed  Google Scholar 

  • Romme-Christensen J, Bornsen L, Khademi M, Olsson T, Jensen PE, Sorensen PS, Sellebjerg F (2013) CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Multiple Sclerosis 19:877–884

    Article  PubMed  Google Scholar 

  • Rosen H, Karlsson JE, Rosengren L (2004) CSF levels of neurofilament is a valuable predictor of long-term outcome after cardiac arrest. J Neurol Sci 221:19–24

    Article  CAS  PubMed  Google Scholar 

  • Rosengren LE, Lycke J, Andersen O (1995) Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit. J Neurol Sci 133:61–65

    Article  CAS  PubMed  Google Scholar 

  • Rundgren M, Friberg H, Cronberg T, Romner B, Petzold A (2012) Serial soluble neurofilament heavy chain in plasma as a marker of brain injury after cardiac arrest. Crit Care 16(2):R45

    Article  PubMed Central  PubMed  Google Scholar 

  • Salzer J, Svenningsson A, Sundstrom P (2010) Neurofilament light as a prognostic marker in multiple sclerosis. Multiple Sclerosis 16:287–292

    Article  CAS  PubMed  Google Scholar 

  • Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, Ebers GC (2010) The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 133:1914–1929

    Article  PubMed Central  PubMed  Google Scholar 

  • Scott D, Smith KE, O’Brien BJ, Angelides KJ (1985) Characterization of mammalian neurofilament triplet proteins. Subunit stoichiometry and morphology of native and reconstituted filaments. J Biol Chem 260:10736–10747

    CAS  PubMed  Google Scholar 

  • Semra YK, Seidi OA, Sharief MK (2002) Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol 122:132–139

    Article  CAS  PubMed  Google Scholar 

  • Shaw G, Yang C, Ellis R, Anderson K, Parker Mickle J, Scheff S, Pike B, Anderson DK, Howland DR (2005) Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury. Biochem Biophys Res Commun 336:1268–1277

    Article  CAS  PubMed  Google Scholar 

  • Shimizu Y, Ota K, Ikeguchi R, Kubo S, Kabasawa, C, Uchiyama S (2013) Plasma osteopontin levels are associated with disease activity in the patients with multiple sclerosis and neuromyelitis optica. J Neuroimmunol 263:148–151

    Article  CAS  PubMed  Google Scholar 

  • Szalardy L, Zadori D, Simu M, Bencsik K, Vecsei L, Klivenyi P (2013) Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity. J Neurol Sci 331:38–42

    Article  CAS  PubMed  Google Scholar 

  • Teunissen CE, Iacobaeus E, Khademi M, Brundin L, Norgren N, Koel-Simmelink MJ, Schepens M, Bouwman F, Twaalfhoven HA, Blom HJ, Jakobs C, Dijkstra CD (2009a) Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 72:1322–1329

    Article  CAS  PubMed  Google Scholar 

  • Teunissen CE, Menge T, Altintas A, Alvarez-Cermeno JC, Bertolotto A, Berven FS, Brundin L, Comabella M, Degn M, Deisenhammer F, Fazekas F, Franciotta D, Frederiksen JL, Galimberti D, Gnanapavan S, Hegen H, Hemmer B, Hintzen R, Hughes S, Iacobaeus E, Kroksveen AC, Kuhle J, Richert J, Tumani H, Villar LM, Drulovic J, Dujmovic I, Khalil M, Bartos A (2013) Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Multiple Sclerosis 19(13):1802–1809

    Article  PubMed  Google Scholar 

  • Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Frederiksen JL, Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Johnson MH, Krasulova E, Kuhle J, Magnone MC, Rajda C, Rejdak K, Schmidt HK, van Pesch V, Waubant E, Wolf C, Giovannoni G, Hemmer B, Tumani H, Deisenhammer F (2009b) A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73:1914–1922

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Teunissen CE, Tumani H, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Federiksen JL, Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Jimenez CR, Johnson MH, Killestein J, Krasulova E, Kuhle J, Magnone MC, Petzold A, Rajda C, Rejdak K, Schmidt HK, van Pesch V, Waubant E, Wolf C, Deisenhammer F, Giovannoni G, Hemmer B (2011) Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. Multiple Sclerosis Int 2011:246412

    Google Scholar 

  • Teunissen CE, Tumani H, Engelborghs S, Mollenhauer B (2014) Biobanking of CSF: International standardization to optimize biomarker development. Clin Biochem 47:288–292

    Article  PubMed  Google Scholar 

  • Tortelli R, Ruggieri M, Cortese R, D’Errico E, Capozzo R, Leo A, Mastrapasqua M, Zoccolella S, Leante R, Livrea P, Logroscino G, Simone IL (2012) Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol 19:1561–1567

    Article  CAS  PubMed  Google Scholar 

  • Tourtellotte WW, Walsh MJ, Baumhefner RW, Staugaitis SM, Shapshak P (1984) The current status of multiple sclerosis intra-blood-brain-barrier IgG synthesis. Ann NY Acad Sci 436:52–67

    Article  CAS  PubMed  Google Scholar 

  • Van Geel WJ, Rosengren LE, Verbeek MM (2005) An enzyme immunoassay to quantify neurofilament light chain in cerebrospinal fluid. J Immunol Methods 296:179–185

    Article  PubMed  Google Scholar 

  • Waubant E, Goodkin D, Bostrom A, Bacchetti P, Hietpas J, Lindberg R, Leppert D (2003) IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology 60:52–57

    Article  CAS  PubMed  Google Scholar 

  • Yabe JT, Chylinski T, Wang FS, Pimenta A, Kattar SD, Linsley MD, Chan WK, Shea TB (2001) Neurofilaments consist of distinct populations that can be distinguished by C-terminal phosphorylation, bundling, and axonal transport rate in growing axonal neurites. J Neurosci 21:2195–2205

    CAS  PubMed  Google Scholar 

  • Yuceyar N, Taskiran D, Sagduyu A (2001) Serum and cerebrospinal fluid nitrite and nitrate levels in relapsing-remitting and secondary progressive multiple sclerosis patients. Clin Neurol Neurosurg 103:206–211

    Article  CAS  PubMed  Google Scholar 

  • Yushchenko M, Mader M, Elitok E, Bitsch A, Dressel A, Tumani H, Bogumil T, Kitze B, Poser S, Weber F (2003) Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis. J Neurol 250:1224–1228

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Neuroscience and Trauma, Blizard Institute, Barts and The London School of Medicine and Dentistry, Blizard Building, 4 Newark Street, London, E1 2AT, UK

    Sharmilee Gnanapavan & Gavin Giovannoni

Authors
  1. Sharmilee Gnanapavan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gavin Giovannoni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sharmilee Gnanapavan .

Editor information

Editors and Affiliations

  1. School of Biological Sciences, Malaghan Institute of Medical Research, Victoria University of Wellington School of Biological Sciences, Wellington, Wellington, New Zealand

    Anne C. La Flamme

  2. Department of Biochemistry, School of Molecular Sciences La Trobe Institute for Molecular Science, Melbourne, Australia

    Jacqueline Monique Orian

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Gnanapavan, S., Giovannoni, G. (2014). Developing Biomarkers for MS. In: La Flamme, A., Orian, J. (eds) Emerging and Evolving Topics in Multiple Sclerosis Pathogenesis and Treatments. Current Topics in Behavioral Neurosciences, vol 26. Springer, Cham. https://doi.org/10.1007/7854_2014_362

Download citation

Publish with us

Policies and ethics

Search

Navigation